3034802-05-3
Chemical Structure
Zoldonrasib
Synonym(s): RMC-9805; KRAS G12D inhibitor 18
- CAS No.: 3034802-05-3
- Formula:C63H88F3N11O7
- Molecular Weight:1168.44
InChIKey: VKNNQJWNUPSOEK-VCAAAJMFSA-N
SMILES: O=C([C@H]1NN(C([C@@H](NC([C@@H](N2C[C@]3(CN(C([C@@H]4N(C)[C@@H]4C5CC5)=O)CC3)CC2)C6CCCC6)=O)C[C@H]7CN8CCO7)=O)CCC1)OCC(C)(C)CC9=[C@@]([C@@]%10=C([C@@H](OC)C)N=CC(N%11CCN(C%12CC%12)CC%11)=C%10)N(CC(F)(F)F)C%13=C9C=C8C=C%13
Biological Activity: Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zoldonrasib | 99.52% | Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. BLAKE JAMES F, et al. Preparation of peptide-linked macrocyclic dipeptides as Ras inhibitors.World Intellectual Property Organization, WO2023060253 A1 2023-04-13
- [2]. Knox, J et al.RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models. Cancer Res 1 April 2023; 83 (7_Supplement): 3475
Keywords
